Get notified of page updates

BRIP1: Options for Cancer Treatment

Learn about personalized treatment options for people with a BRIP1 mutation. Stay up to date by signing up for our community newsletter.
Glossary on
off

Cancer Treatment for People with Inherited Mutations

Inherited mutations may affect treatment options or eligibility for clinical trials studying which treatments work best. 

If you have an inherited  mutation, have been diagnosed with cancer and any of the situations below apply to you, you may wish to speak to your doctor about your medical options. 

Regardless of cancer type, people with a  mutation may benefit from testing and may qualify for clinical trials looking for more effective treatments for cancer.


Targeted therapies for advanced cancers

PARP inhibitors are a type of that work by blocking a protein used to repair damaged . People with a mutation who have been diagnosed with cancer may want to ask their doctor about whether they might benefit from a clinical trial or treatment with a

PARP inhibitors for prostate cancer

The , Lynparza () has received FDA-approval to treat men with , castration-resistent cancer, who have a mutation in  or another gene linked to a certain type of damage repair. Lynparza may be used to treat men whose cancer has progressed on  (Xtandi) or (Zytiga). 
 

PARP inhibitors for advanced ovarian, or primary peritoneal cancer

Several PARP inhibitors have been approved to treat ovarian cancers at different stages of the disease. In some situations, a tumor known as an  test ("hemologous recombination deficiency") can help women with an inherited  mutation and advanced ovarian cancer learn if they may benefit from a .

after treatment

  • testing can help women with advanced ovarian cancer learn if they may benefit from the Lynparza in combination with bevacizumab as  after platinum chemotherapy.
  •  is approved for  in women with advanced ovarian, , or primary peritoneal cancer who had a complete or partial response to platinum-based chemotherapy. for does not require an test. 

after treatment of recurrent cancer

  • , () and Lynparza are all approved for maintenance therapy in women with recurrent epithelial ovarian, , or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy. In this setting, none of these drugs requires an  test. 
     

PARP inhibitors or other targeted therapies for advanced cancers with no other treatment options

If you have a mutation and advanced cancer that no longer responds to standard therapy, you may have additional options. Talk with your doctor about tumor testing to learn whether you might benefit from a , another or participation in a clinical trial. 

Last updated June 22, 2024